title: Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management.
abstract: Ipilimumab is a human anti-CTLA-4 monoclonal antibody recently approved for the treatment of advanced melanoma. Stimulation of T-cell activity unmasks antitumor activity, but can cause immune-related adverse events. Autoimmune hypophysitis is of particular importance because its presentation can be subtle but life threatening. We present two cases where early recognition of ipilimumab-related autoimmune hypophysitis led to timely intervention and low subsequent morbidity, without compromise of antitumor effects. We provide recommendations for detection and management of this potentially life-threatening complication of ipilimumab.
authors: Department of Medical Oncology, Eastern Health, Box Hill, Victoria, Australia.
authors: Crescens
authors: C
authors: Tiu
authors: Carmel
authors: C
authors: Pezaro
authors: Ian D
authors: ID
authors: Davis
authors: Mathis
authors: M
authors: Grossmann
authors: Phillip
authors: P
authors: Parente
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000069281:Autoimmune Hypophysitis / Q000139:chemically induced*; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000150:complications* / Q000473:pathology; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab
keywords: CTLA-4; autoimmune hypophysitis; ipilimumab; melanoma